NIH study finds antiviral drug effective against Covid-19 19 Apr 2021 (Last Updated April 19th, 2021 16:04)
The National Institutes of Health (NIH) has reported results from a study that showed that experimental antiviral drug MK-4482 (molnupiravir and EIDD-2801) significantly lowered viral levels and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection.
Share Article
The National Institutes of Health (NIH) has reported results from a study that showed that experimental antiviral drug MK-4482 (molnupiravir and EIDD-2801) significantly lowered viral levels and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection.
With NIAID funding, MK-4482 was developed by Emory University’s Drug Innovation Ventures group in Atlanta, US for treating influenza.
Experimental Drug MK-4482 for COVID-19 Is Effective in Hamster Study technologynetworks.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from technologynetworks.com Daily Mail and Mail on Sunday newspapers.
Experimental antiviral drug for COVID-19 shows effectiveness in hamster models
The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from National Institutes of Health scientists. SARS-CoV-2 is the virus that causes COVID-19. MK-4482, delivered orally, is now in human clinical trials. Remdesivir, an antiviral drug already approved by the U.S. Food and Drug Administration for use against COVID-19, must be provided intravenously, making its use primarily limited to clinical settings.
In their study, published in the journal
Nature Communications, the scientists found MK-4482 treatment effective when provided up to 12 hours before or 12 hours after infecting the hamsters with SARS-CoV-2. These data suggest that MK-4482 treatment potentially could mitigate high-risk exposures to SARS-CoV-2, and might be used to treat established SARS-CoV-2 infection alone o
Experimental antiviral drug effective against Covid: Study
By IANS |
5 Views
US coronavirus death toll mounts to 6, Trump wants vaccine at âmaximum speedâ.. Image Source: IANS News
New York, April 18 : An experimental oral antiviral drug has shown potential in prevention and treatment of SARS-CoV-2, the virus causing Covid-19 infections, say researchers.
The antiviral MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from the US National Institutes of Health scientists. MK-4482 is currently undergoing human clinical trials.
In the study, published in the journal Nature Communications, the scientists found MK-4482 treatment effective when provided up to 12 hours before or 12 hours after infecting the hamsters with SARS-CoV-2.
Fermenta Biotech brings multiple routes to synthesise Molnupiravir for COVID-19 treatment
Fermenta Biotech brings multiple routes to synthesise Molnupiravir for COVID-19 treatment
16 April 2021 | News Pioneers the development of its patented enzymatic route of synthesis for Molunpiravir an investigational ‘orally active’ therapeutic alternative for COVID-19
Image credit- shutterstock.com
Fermenta Biotech Limited (FBL) has announced that it has successfully developed and filed patent application(s) for novel biocatalytic technology of manufacturing Molnupiravir.
The patented enzymatic route of synthesis possesses the technological advantage of being efficient and environment-friendly, with higher yields and lower solvent use as compared to existing reported manufacturing processes. Biocatalysis is defined as the use of natural substances that include enzymes from biological sources or whole cells to speed up chemical reactions.